Last Update Time:
17-Mar-2025 15:53:57
ISIN:
INE794A01010
Sector:
Healthcare
Symbol:
NEULANDLAB
Neuland Laboratories Limited
₹10,795.00
₹-275.60
(-2.49%)
▼
Prev. Close
₹11,070.60
Open
₹11,200.45
Close
₹0.00
Range
₹10,255.25 - ₹11,334.75
High
₹11,265.00
Low
₹10,740.10
Ind. Close
₹0.00
VWAP
₹10,961.97
The current stock price of Neuland Laboratories Limited is ₹10,795.00, with a target price range between ₹10,255.25 and ₹11,334.75. The stock has experienced a price change of ₹-275.60 (-2.49%), reflecting recent market volatility.
Today's opening price was ₹11,200.45, while the previous close stood at ₹11,070.60.
The market trend suggests a potential downtrend, with investors exercising caution due to recent declines. Analysts recommend closely monitoring support levels.
For real-time stock market updates, live share prices, and stock analysis, stay tuned. Understanding key stock metrics like VWAP, high-low range, and market momentum can help traders make informed investment decisions.
Neuland Laboratories Limited Price Chart
Neuland Laboratories Limited Pre Open Market Overview: 17-Mar-2025
Key Metrics:
- IEP (Indicative Equilibrium Price): 11200.45
- Previous Close Price: 11070.6
- Change: 129.85%
- Total Traded Volume: 136
- Total Buy Quantity: 519
- Total Sell Quantity: 1,040
| Price | Buy Qty | Sell Qty |
|---|---|---|
| 11,106.00 | 1.00 | 0.00 |
| 11,125.95 | 1.00 | 0.00 |
| 11,135.80 | 10.00 | 0.00 |
| 11,155.00 | 1.00 | 0.00 |
| 11,168.30 | 10.00 | 0.00 |
| 11,200.45 | 0.00 | 5.00 |
| 11,200.80 | 0.00 | 17.00 |
| 11,331.00 | 0.00 | 2.00 |
| 11,400.00 | 0.00 | 41.00 |
| 11,422.20 | 0.00 | 3.00 |
ATO Data:
- Buy Quantity (ATO): 0
- Sell Quantity (ATO): 0
Order Book
| Bid | Qty | Ask | Qty |
|---|---|---|---|
| 10,797.40 | 3 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
Total Buy Quantity: 519
Total Sell Quantity: 1040
Shareholding Patterns of Neuland Laboratories Limited
Key Trade Statistics of Neuland Laboratories Limited
| Trade Information | Details |
|---|---|
| Traded Volume (Lakhs) | 0.30 |
| Traded Value (₹ Cr.) | 32.60 |
| Total Market Cap (₹ Cr.) | 13,849.87 |
| Free Float Market Cap (₹ Cr.) | 9,277.93 |
| Impact cost | 0.06 |
| Quantity Traded | 22,487.00 |
| Deliverable Quantity | 9,415.00 |
| % of Quantity to Traded | 41.87 |
| Security VaR | 23.55 |
| Index VaR | N/A |
| VaR Margin | 23.55 |
| Extreme Loss Rate | 3.5 |
| Adhoc Margin | N/A |
| Applicable Margin Rate | 27.05 |
| Face Value | 10 |
Key Price Statistics of Neuland Laboratories Limited
The 52-week high for Neuland Laboratories Limited was ₹18,100.00, recorded on 04-Dec-2024. On the other hand, the 52-week low stands at ₹5,540.10, with the lowest value recorded on 04-Jun-2024.
The upper band for trading is ₹13,284.70, and the lower band is ₹8,856.50. The price band is 20%.
The stock's daily volatility stands at 3.53, while the annualized volatility is 67.44. The tick size for trading is ₹0.05.
| Price Information | Details |
|---|---|
| 52 Week High (04-Dec-2024) | 18,100.00 |
| 52 Week Low (04-Jun-2024) | 5,540.10 |
| Upper Band | 13,284.70 |
| Lower Band | 8,856.50 |
| Price Band (%) | 20 |
| Daily Volatility | 3.53 |
| Annualised Volatility | 67.44 |
| Tick Size | 0.05 |
Key Securities Statistics of Neuland Laboratories Limited
| Securities Information | Details |
|---|---|
| Status | Listed |
| Trading Status | Active |
| Date of Listing | 13-Oct-2008 |
| Adjusted P/E | 59.38 |
| Symbol P/E | 47.37 |
| Index | NIFTY TOTAL MARKET |
| Macro-Economic Sector | Healthcare |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Basic Industry | Pharmaceuticals |
Security Status of Neuland Laboratories Limited
| Title | Details |
|---|---|
| Board Status | Main |
| Trading Segment | Normal Market |
| Session No. | - |
| Class of Shares | Equity |
| SDD Compliance | - |
| Name of Compliance Officer | - |
Announcements of Neuland Laboratories Limited
| Subject | Date |
|---|---|
| Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent | 10-Mar-2025 |
| Credit Rating | 10-Mar-2025 |
| Change in Management | 10-Mar-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 27-Feb-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 14-Feb-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 11-Feb-2025 |
| Copy of Newspaper Publication | 11-Feb-2025 |
| Integrated Filing- Financial | 10-Feb-2025 |
Corporate Actions of Neuland Laboratories Limited
| Face Value | Purpose | Ex-Date |
|---|---|---|
| 10 | Annual General Meeting/Dividend - Rs 14 Per Share | 12-Jul-2024 |
| 10 | Annual General Meeting/Dividend - Rs 10 Per Share | 11-Jul-2023 |
| 10 | Annual General Meeting/Dividend - Rs 5 Per Share | 14-Jul-2022 |
| 10 | Annual General Meeting/Dividend - Rs 3 Per Share | 29-Jun-2021 |
| 10 | Interim Dividend - Rs 2 Per Share | 10-Nov-2020 |
| 10 | Annual General Meeting | 02-Jul-2020 |
| 10 | Interim Dividend - Rs 2 Per Share | 18-Feb-2020 |
| 10 | Annual General Meeting/Dividend - Rs 1.20 Per Share | 27-Jun-2019 |
| 10 | Annual General Meeting | 03-Aug-2018 |
| 10 | Annual General Meeting (Date Revised) | 21-Dec-2017 |
| 10 | Annual General Meeting/ Dividend - Rs 2/- Per Share | 04-Aug-2016 |
| 10 | Annual General Meeting/Dividend Rs 1.50 Per Share | 06-Aug-2015 |
| 10 | Rights Issue 4 : 25 @ Premium Rs 194/- Per Equity Share | 13-Aug-2014 |
| 10 | Annual General Meeting/Final Dividend Rs.1.50 Per Share And Special Dividend Rs.1.50 Per Share | 16-Jun-2014 |
| 10 | Annual General Meeting And Dividend Rs.1.20 Per Share | 24-Jul-2013 |
| 10 | Annual General Meeting | 03-Aug-2012 |
| 10 | Rights 5:12 @ Premium Rs.35/- Per Share | 21-Mar-2012 |
| 10 | Annual General Meeting | 29-Jul-2011 |
| 10 | Annual General Meeting | 22-Jul-2010 |
| 10 | Div. -Rs.3.50/-Per Share | 13-Jul-2009 |
Board Meetings of Neuland Laboratories Limited
Financial Results of Neuland Laboratories Limited
Company Directory of Neuland Laboratories Limited
| Web Address | Office | Address | City |
|---|---|---|---|
| www.neulandlabs.com | Registered Office | 11th Floor (5th Level), Phoenix IVY Building, Plot No. 573A-III, Road No. 82, Jubilee Hills, Hyderabad | HYDERABAD |
| www.neulandlabs.com | Transfer Agent | KFin Technologies Limited Selenium Tower B, Plot No 31 & 32, Financial District, Nanakramguda, Serilingampally, Hyderabad- 500 032, | HYDERABAD |
Insider Trading of Neuland Laboratories Limited
| Reg. Clause | Acq./Disp. | Sec. Value | Txn Type |
|---|---|---|---|
| 7(2) | Saharsh Rao Davuluri | 0 | Sell |
| 7(2) | Davuluri Ownership Trust | 0 | Buy |
| 7(2) | Sucheth Rao Davuluri | 0 | Sell |
| 7(2) | Davuluri Vijaya Rao | 0 | Sell |
| 7(2) | Davuluri Ramamohan Rao | 0 | Sell |
| 7(2) | Davuluri Ownership Trust | 0 | Buy |
| 7(2) | Nirupama Sundar | 2687656 | Sell |
| 7(2) | Davuluri Ramamohan Rao | 0 | Sell |
| 7(2) | Davuluri Saharsh Rao | 0 | Buy |
| 7(2) | Payal Gupta | 1619375 | Buy |
| 7(2) | Nirupama Sundar | 1039089 | Buy |
| 7(2) | Davuluri Rohini Niveditha Rao | 0 | Sell |
| 7(2) | Gannabathula Venkata Krishna Rama Rao | 2243610 | Sell |
| 7(2) | Gannabathula Veeravenkata Satyanarayanamurthy | 1255000 | Sell |
| 7(2) | SRINIVASA KRISHNA MOHAN DAVULURI | 1687752 | Sell |
| 7(2) | Gannabathula Venkata Krishna Rama Rao | 1331250 | Sell |
| 7(2) | Gannabathula Veeravenkata Satyanarayanamurthy | 1331250 | Sell |
| 7(2) | Gannabathula Veeravenkata Satyanarayanamurthy | 1051365 | Sell |
| 7(2) | Gannabathula Venkata Krishna Rama Rao | 1018768 | Sell |
| 7(2) | Davuluri Saharsh Rao | 2945540 | Buy |
Annual Reports of Neuland Laboratories Limited
Investor Complaints of Neuland Laboratories Limited
Event Calendar of Neuland Laboratories Limited
| Purpose | Details |
|---|---|
| Board meeting Rescheduled | The Company had informed the exchange that a meeting of the Board of Directors will be held on May 28, 2010 to consider and take on record the Annual Audited Results of the company for the year ended March 31, 2010. The Company has now informed the exchange that the meeting of the Board of Directors of the Company is scheduled to be held on May 29, 2010 to consider and take on record the Annual Audited Results of the company for the year ended March 31, 2010. |
| Results/Dividend | To inter-alia consider the audited financial results of the company for the year ended March 31, 2011 and consider recommendation of dividend, if any. |
| Rights Issue | Inter-alia to consider the issue of equity shares on rights issue basis to the members of the Company. |
| Rights Issue | Inter-alia to consider the issue of equity shares on right issue basis to the members of the Company. |
| Rights Issue | Inter alia, (1) To approve the Record Date for the purpose of deciding the shareholders who are eligible to apply for Equity Shares on rights basis in the proposed Issue, (2) To approve the size of the Issue, Issue price, ratio of Rights Entitlement, and other matters pertaining to the issue; (3) To approve the restated financial statement of the Company; (4) To ratify the appointment of bankers to the Issue; (5) To approve the Letter of Offer. |
| Results | Inter-alia to consider the unaudited financial results of the company for the quarter ended 31st December, 2012. |
| Results | Inter-alia to consider and take on record the audited financial results of the Company for the year ended March 31, 2013 and to consider and recommend dividend, if any. |
| Results | Inter-alia, to consider and take on record the unaudited financial results of the Company for the quarter ended June 30, 2013. |
| Results | Inter-alia to consider and take on record the unaudited financial results of the Company for the quarter ended September 30, 2013. |
| Results | inter alia, to consider and take on record the unaudited financial results of the Company for the quarter ended December 31, 2013. Further, as per the provisions of the Code of Conduct for Prevention of Insider Trading of the Company, the Trading Window for transactions in shares of the Company is closed from January 21, 2014 to February 06, 2014 (both days inclusive), inter alia, for the purpose of announcement of the Unaudited Financial Results by the Company. |
| Rights Issue | Neuland Laboratories Limited has informed the Exchange that Board Meeting scheduled on February 5, 2014 would consider and take on record the unaudited financial results of the Company for the quarter ended December 31, 2013. The Company has now informed that Board would also consider the issue of equity shares on rights basis to the members of the Company, along with the unaudited financial results for the quarter ended December 31, 2013. (purpose revised) |
| Results/Dividend | To consider and take on record the audited financial results of the Company for the year ended March 31, 2014 and to consider and recommend dividend, if any. Further, as per the provisions of the Code of Conduct for Prevention of Insider Trading of the Company, the Trading Window for transactions in shares of the Company is closed from April 24, 2014 to May 12, 2014 (both days inclusive), inter alia, for the purpose of announcement of the Audited Financial Results by the Company. |
| Results | Inter-alia to consider and take on record the un-audited financial results of the Company for the quarter ended June 30, 2014. Further, the Company has informed the Exchange that as per the provisions of the Code of Conduct for Prevention of Insider Trading of the Company, the Trading Window for transactions in shares of the Company is closed from July 17, 2014 to August 5, 2014 (both days inclusive), inter alia, for the purpose of announcement of the un-audited Financial Results by the Company. |
| Results/Rights | The Company had informed the Exchange regarding a meeting of the Board of Directors of the Company will be held on August 01, 2014 Inter-alia to consider and take on record the un-audited financial results of the Company for the quarter ended June 30, 2014. The company has now informed the Board also consider the following, inter alia, (1)to approve the size of the Rights Issue, Issue price, ratio of Rights Entitlement, and other matters pertaining to the Rights Issue and (2) to approve the Record Date for the purpose of deciding the shareholders who are eligible to apply for Equity Shares on rights basis in the proposed Issue. Also, as per the provisions of the Code of Conduct for Prevention of Insider Trading of the Company, the Trading Window for transactions in shares of the Company is closed from July 17, 2014 to August 4, 2014 (both days inclusive) for the above said purpose.(Purpose Revised) |
| Results | inter-alia to consider and take on record the un-audited financial results of the Company for the quarter ended September 30, 2014. Further as per the provisions of the Code of Conduct for Prevention of Insider Trading of the Company, the Trading Window for transactions in shares of the Company is closed from October 14, 2014 to October 30, 2014 (both days inclusive), inter alia, for the purpose of announcement of the un-audited Financial Results by the Company. |
| Results | inter-alia to consider and take on record the un-audited financial results of the Company for the quarter ended December 31, 2014. |
| Results | Inter-alia to consider and take on record the Audited financial results of the Company for the year ended March 31, 2015. |
| Results/Dividend | The Company had informed the Exchange regarding a meeting of the Board of Directors of the Company schedule to be held on May 8, 2015, Inter-alia to consider and take on record the Audited financial results of the Company for the year ended March 31, 2015.The Company has now informed the Exchange that the Board will also consider payment of Dividend , if any, along with the audited financial results for the year ended March 31, 2015 (purposed revised). |
| Results | inter-alia to consider and take on record the Un-audited financial results of the Company for the quarter ended June 30, 2015. |
| Results | inter-alia to consider and take on record the Un-audited financial results of the Company for the quarter ended September 30, 2015. |
| Results | Inter-alia, to consider and take on record the un-audited financial results of the Company for the quarter ended December 31, 2015. |
| Results/Dividend | inter-alia to consider and take on record the audited financial results of the Company for the year ended March 31, 2016. Further the Board of Directors also consider payment of dividend, if any, along with the audited financial results for the year ended March 31, 2016. |
| Results | Inter-alia to consider and take on record the Un audited financial results of the Company for the quarter ended June 30, 2016. |
| Amalgamation/Merger | inter-alia, to consider a proposal to merge Neuland Health Sciences Private Limited (Holding Company) ( NHSPL ) and Neuland Pharma Research Private Limited (subsidiary of NHSPL) ( NPRPL ) with Neuland Laboratories Limited ( the Company ). |
| Results | Inter-alia to consider and take on record the Un-audited financial results of the Company for the quarter ended September 30, 2016. Company would like to further inform that as per the provisions of the Code of Conduct for Prevention of Insider Trading of the Company, the Trading Window for transactions in shares of the Company is closed from October 14, 2016 to November 6, 2016 (both days inclusive), inter alia, for the purpose of announcement of the Un-audited financial results of the Company for the quarter ended September 30, 2016. |
| Results | inter-alia, to consider and take on record the Un-audited financial results of the Company for the quarter ended September 30, 2016. |
| Results | Inter-alia to consider and take on record the Un-audited financial results of the Company for the quarter ended December 31, 2016. |
| Results | inter-alia to consider and take on record the Audited financial results of the Company for the year ended March 31, 2017. Further the Trading Window for transactions in shares of the Company is closed from April 24, 2017 to May 14, 2017 (both days inclusive) and will be re-opened on May 15, 2017, inter alia, for the purpose of announcement of the Audited financial results of the Company for the year ended March 31, 2017. |
| Results | inter-alia to consider and take on record the Un-audited financial results of the Company for the quarter ended June 30, 2017. |
| Results | NEULANDLAB : inter-alia to consider and take on record the Un-audited financial results of the Company for the quarter ended September 30, 2017 |
| Results | Inter-alia, to consider and take on record the Un-audited financial results of the Company for the quarter ended December 31, 2017. |
| Fund Raising | A meeting of the Board of Directors of the Company is scheduled to be held on Monday, April 9, 2018, inter alia, to consider a proposal for raising funds by way of issuance of equity shares or equity linked securities such as warrants or convertible securities including but not limited to through preferential issue and/or qualified institutions placement or through any other permissible mode and/or combination thereof as may be considered appropriate, subject to approvals as may be required including approval of the Shareholders at a general meeting or through postal ballot and the same would be subject to such other regulatory/statutory approvals as may be applicable. Also, Trading Window for dealing in the securities of the Company shall remain closed till April 11, 2018. |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2018 |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2018 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2018 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2018 |
| Financial Results | To consider and approve the audited financial results for the period ended March 31, 2019 |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2019 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2019 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2019 |
| Financial Results/Dividend | the Board of Directors of the Company at its meeting held on February 11, 2020To consider and approve the financial results for the period ended December 31, 2019. The company has now inform the exchange that the Board of Directors of the Company also consider the recommendation of Interim Dividend for the financial year 2019-20, |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2020 |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2020 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended September 30, 2020 and recommendation of interim dividend, if any |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2020 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2020 |
| Financial Results/Dividend | To consider and approve the Audited Financial Results for the period ended March 31, 2021 and to recommend final dividend if any |
| Financial Results/Other business matters | To consider and approve the financial results for the quarter ended June 30, 2021 and other business matters |
| Financial Results/Other business matters | To consider and approve the unaudited financial results for the quarter and half year ended September 30, 2021 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2021 |
| Financial results | Neuland Laboratories Limited has informed the Exchange about Board Meeting to be held on 03-Aug-2022 to consider financial statements for the period ended June 2022 |
| Financial results | Board Meeting Intimation for Considering And Approving The Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2022 |
| Financial Results | To consider and approve the unaudited Financial Results for the quarter and nine months ended December 31, 2022 |
| Financial Results/Dividend | Meeting of the Board of Directors of the Company is scheduled to be held on Thursday, May 11, 2023, inter-alia to a) consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended March 31, 2023, and; b) recommend final dividend, if any, for the financial year ended March 31, 2023 |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2023 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2023 |
| Financial Results | To consider and approve the unaudited Financial Results of the Company for the Quarter and nine months ended December 31, 2023 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2024 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2024 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2024 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2024 |
Share Transfers of Neuland Laboratories Limited
Voting Results of Neuland Laboratories Limited
| Date of Mtg. | Mtg. Type | Resolution |
|---|---|---|
| 31-JUL-2024 | AGM | To receive, consider and adopt: (a) the Audited Financial Statements of the Company for the financial year ended March 31, 2024, together with the reports of the Board of Directors and the Auditors￢ﾀﾙ thereon; and (b) the Audited Consolidated Financial Statements of the Company for the financial year ended March 31, 2024, together with the report of the Auditors thereon |
| 31-JUL-2024 | AGM | Ratification of remuneration of Cost Auditors |
| 31-JUL-2024 | AGM | To reappoint statutory auditors of the Company and fix their remuneration |
| 31-JUL-2024 | AGM | To appoint a Director in place of Mr. Davuluri Sucheth Rao (DIN: 00108880) who retires by rotation and, being eligible, offers himself for re-appointment |
| 31-JUL-2024 | AGM | To appoint a Director in place of Dr. Davuluri Rama Mohan Rao (DIN: 00107737) who retires by rotation and, being eligible, offers himself for re-appointment |
| 31-JUL-2024 | AGM | To declare final dividend of Rs. 14.00/- [140 %] per equity share of a face value of Rs.10 each, for the financial year 2023-24 as recommended by the Board |
| 27-JUL-2023 | AGM | To receive, consider and adopt: (a) the Audited Financial Statements of the Company for the financial year ended March 31, 2023, together with the reports of the Board of Directors and the Auditors￢ﾀﾙ thereon; and (b) the Audited Consolidated Financial Statements of the Company for the financial year ended March 31, 2023, together with the report of the Auditors thereon |
| 27-JUL-2023 | AGM | Ratification of remuneration of Cost Auditors |
| 27-JUL-2023 | AGM | Revision in remuneration payable to Mr. Davuluri Saharsh Rao (DIN: 02753145), Whole Time Director, designated as Vice Chairman & Managing Director |
| 27-JUL-2023 | AGM | Re-appointment of Dr. Davuluri Rama Mohan Rao (DIN: 00107737), as Whole Time Director, designated as Executive Chairman |
| 27-JUL-2023 | AGM | Re-appointment of Mr. Homi Rustam Khusrokhan (DIN: 00005085), as an Independent Director of the Company for a further period of five years |
| 27-JUL-2023 | AGM | Continuation of directorship of Mrs. Bharati Rao (DIN: 01892516), as Non-Executive Independent Director on attaining the age of 75 years |
| 27-JUL-2023 | AGM | Appointment of Ms. Pallavi Bhakru (DIN: 01526618), as an Independent Director of the Company |
| 27-JUL-2023 | AGM | Appointment of Mr. Sugata Sircar (DIN: 01119161), as an Independent Director of the Company |
| 27-JUL-2023 | AGM | Re-appointment of Mr. Davuluri Sucheth Rao (DIN: 00108880), as Whole Time Director, designated as Vice Chairman & Chief Executive Officer |
| 27-JUL-2023 | AGM | To adopt a new set of Articles of Association of the Company as per the Companies Act, 2013 |
| 27-JUL-2023 | AGM | To appoint a Director in place of Dr.Christopher Cimarusti (DIN: 02872948) who retires by rotation and, being eligible, offers himself for re-appointment |
| 27-JUL-2023 | AGM | To declare final dividend of Rs. 10.00/- [100 %] per equity share of a face value of Rs.10 each, for the financial year 2022-23 as recommended by the Board |
| 22-DEC-2022 | Postal Ballot | To approve the appointment of Mr. Prasad Raghava Menon (DIN: 00005078), as an Independent Director of the Company |
| 02-AUG-2022 | AGM | To receive, consider and adopt (a) the Audited Financial Statements of the Company for the financial year ended March 31, 2022, together with the reports of the Board of Directors and the Auditors￢ﾀﾙ thereon and (b) the Audited Consolidated Financial Statements of the Company for the financial year ended March 31, 2022, together with the report of the Auditors thereon. |
FAQs on Neuland Laboratories Limited
Disclaimer: The information provided here is for informational purposes only and should not be considered financial advice. Please do your own research and consult with a financial professional before making any investment decisions.